Studies have shown that KDM5A promotes the resistance of breast cancer cells to clinical drugs such as trastuzumab and erlotinib by blocking the regulation of p21 and BCL2-antagonist/killer 1 (Bak1) (Hou et al., 2012; Choi et al., 2018). Here, BCL2 is linked to breast carcinoma.